Good
Partially Aligned
Patient Risk:
Low
Summary
Most non-indication claims are generally consistent with how biologics/biosimilars and exclusivity/patents function, but the provided label excerpts do not contain sufficient on-label text to support or verify several biosimilar/exclusivity/patent assertions. Claims about Yervoy being biologic and being ipilimumab are consistent with the provided active ingredient description.
Category Scores
Accurate Statements
Yervoy is a biologic medicine (ipilimumab).
Supported by the provided context: 'Active ingredient: ipilimumab (human monoclonal antibody; anti–CTLA-4)' and label excerpt indicates YERVOY is ipilimumab.
Yervoy is a biologic medicine (ipilimumab).
Supported by the provided context description of ipilimumab as a human monoclonal antibody.
Unsupported Statements
Yervoy does not have a traditional generic equivalent in the way small-molecule drugs do.
The provided FDA label excerpts do not address generic-equivalent status or eligibility for traditional small-molecule generics.
Biologic medicines can have biosimilars if regulators approve them.
The provided label excerpts do not contain statements about biosimilar regulatory pathways.
Yervoy biosimilars would depend on whether any are approved or near approval.
The provided label excerpts do not discuss the existence/approval status or 'near approval' status of biosimilars.
Whether a biosimilar can enter depends on when Yervoy’s patents and exclusivity expire.
The provided label excerpts do not mention patents, exclusivity, or market entry timing for biosimilars.
Contradictions
Important Omissions
No indication, dosage, contraindications, boxed warnings, precautions, drug interactions, adverse reactions, administration, or monitoring claims were evaluated because the audit claims provided were about biologics/biosimilars/patents rather than label-based clinical content.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The biosimilar/patent/generic-status claims are not directly tied to specific dosing, contraindications, or safety outcomes in the provided excerpts. However, several statements are unsupported by the provided on-label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple biosimilar/patent/exclusivity claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what the label excerpts explicitly support (e.g., YERVOY active ingredient as ipilimumab). If making biosimilar/patent/exclusivity statements, cite specific label language if available in the provided prescribing information, or remove those assertions from the audited response.